INBX

Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology. The company's lead program targets alpha-fetoprotein (AFP)-positive tumors, including hepatocellular carcinoma, using a novel T cell engager platform. Inhibrx Biosciences leverages its proprietary single-domain antibody technology to create multi-specific therapeutics designed to redirect immune cells to tumor sites. The company's pipeline includes programs addressing difficult-to-treat solid tumors with high unmet medical needs.